<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Favipiravir was also approved on February 15, 2020, in China against COVID-19 after clinical trial by the Clinical Medical Research Centre of the National Infectious Diseases and the Third Peopleâ€™s Hospital of Shenzhen on February 14. In its active form (phosphoribosylated), it pretends as a substate for RNA polymerase [
 <xref ref-type="bibr" rid="CR9">9</xref>] causing suspension of viral growth [
 <xref ref-type="bibr" rid="CR7">7</xref>]. Some Chinese herbs, Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis against SARS-CoV-2 are also under clinical trial.
</p>
